BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 37195776)

  • 1. Novel Approaches and Future Directions in Myelodysplastic Syndrome Treatment.
    Bewersdorf JP; Xie Z; Zeidan AM
    Cancer J; 2023 May-Jun 01; 29(3):195-202. PubMed ID: 37195776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New Approaches to Myelodysplastic Syndrome Treatment.
    Bazinet A; Bravo GM
    Curr Treat Options Oncol; 2022 May; 23(5):668-687. PubMed ID: 35320468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging treatments for myelodysplastic syndromes: Biological rationales and clinical translation.
    Rodriguez-Sevilla JJ; Adema V; Garcia-Manero G; Colla S
    Cell Rep Med; 2023 Feb; 4(2):100940. PubMed ID: 36787738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Raising the bar for lower-risk myelodysplastic syndromes.
    Venugopal S; Sekeres MA
    Leuk Lymphoma; 2023 Jun; 64(6):1082-1091. PubMed ID: 37029589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current Therapeutic Landscape in Lower Risk Myelodysplastic Syndromes.
    Wang C; Sallman DA
    Curr Treat Options Oncol; 2023 May; 24(5):387-408. PubMed ID: 36966266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolving therapies for lower-risk myelodysplastic syndromes.
    Bewersdorf JP; Zeidan AM
    Ann Hematol; 2020 Apr; 99(4):677-692. PubMed ID: 32078008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of Patients with Lower-Risk Myelodysplastic Neoplasms (MDS).
    Lucero J; Al-Harbi S; Yee KWL
    Curr Oncol; 2023 Jun; 30(7):6177-6196. PubMed ID: 37504319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current and emerging strategies for management of myelodysplastic syndromes.
    Saygin C; Carraway HE
    Blood Rev; 2021 Jul; 48():100791. PubMed ID: 33423844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in myelodysplastic syndromes: promising novel agents and combination strategies.
    Madanat YF; Xie Z; Zeidan AM
    Expert Rev Hematol; 2023 Jan; 16(1):51-63. PubMed ID: 36620919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beyond the horizon: emerging therapeutic approaches in myelodysplastic neoplasms.
    Merz AMA; Platzbecker U
    Exp Hematol; 2024 Feb; 130():104130. PubMed ID: 38036096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myelodysplastic syndromes current treatment algorithm 2018.
    Steensma DP
    Blood Cancer J; 2018 May; 8(5):47. PubMed ID: 29795386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk-Adapted, Individualized Treatment Strategies of Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML).
    Bewersdorf JP; Zeidan AM
    Cancers (Basel); 2021 Mar; 13(7):. PubMed ID: 33807279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel therapies in low- and high-risk myelodysplastic syndrome.
    Germing U; Schroeder T; Kaivers J; Kündgen A; Kobbe G; Gattermann N
    Expert Rev Hematol; 2019 Oct; 12(10):893-908. PubMed ID: 31353975
    [No Abstract]   [Full Text] [Related]  

  • 14. Myelodysplastic Syndromes: A New Decade.
    Volpe VO; Garcia-Manero G; Komrokji RS
    Clin Lymphoma Myeloma Leuk; 2022 Jan; 22(1):1-16. PubMed ID: 34544674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosis and Treatment of Myelodysplastic Syndromes: A Review.
    Sekeres MA; Taylor J
    JAMA; 2022 Sep; 328(9):872-880. PubMed ID: 36066514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic Targets in Myelodysplastic Neoplasms: Beyond Hypomethylating Agents.
    Pophali P; Desai SR; Shastri A
    Curr Hematol Malig Rep; 2023 Jun; 18(3):56-67. PubMed ID: 37052811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Management of myelodysplastic syndromes in 2019: An update].
    Comont T; Delavigne K; Cougoul P; Bertoli S; Delabesse E; Fenaux P; Beyne-Rauzy O
    Rev Med Interne; 2019 Sep; 40(9):581-589. PubMed ID: 31054780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management.
    Garcia-Manero G
    Am J Hematol; 2015 Sep; 90(9):831-41. PubMed ID: 26294090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Luspatercept as a therapy for myelodysplastic syndromes with ring sideroblasts.
    Schulz F; Nachtkamp K; Kasprzak A; Gattermann N; Haas R; Germing U
    Expert Rev Hematol; 2021 Jun; 14(6):509-516. PubMed ID: 34161752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management.
    Garcia-Manero G
    Am J Hematol; 2012 Jul; 87(7):692-701. PubMed ID: 22696212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.